abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
94514: Multiple Myeloma, Daratumumab-specific, Immunofixation Print View
Interpretation      

PRIMARY
1 Serum 2 (1) mL   Room Temperature - 5 Day(s)/Refrigerated - 6 Day(s)/Frozen - 6 Month(s)  
ALTERNATE

Daratumumab is an anti-CD38 IgGk monoclonal antibody currently in clinical development for multiple myeloma (MM) treatment. In MM, malignant cells secrete high levels of monoclonal immunoglobulin (M-protein) that is commonly detectable by serum immunofixation electrophoresis (IFE). As immunoglobulin, daratumumab also can be detected in IFE and may co-migrate with M-protein in a subset of patients (50% of MM patient produce IgGk M protein). Addition of anti-idiotypic antibodies raised against daratumumab to patient serum containing daratumumab alters banding pattern as assessed by IFE (daratumumab shift) by forming a daratumumab and anti-daratumumab complex, helping to distinguish between therapeutic monoclonal antibody and M-protein present in the serum.

Patient Preparation: Overnight fasting is preferred.
Setup Schedule
Sunday-Friday

Reported (Analytical Time)
4 days

CPT Code
86334

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
Reject Criteria: Specimens other than serum
Transport Temperature: Refrigerated
Methodology: Immunofixation






1996 - 2018 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database